Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn’s disease: a case report

Overview of attention for article published in Journal of Hematology & Oncology, September 2016

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 62 Dimensions

Readers on

mendeley: 86 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 3,221 followers.

RT @LucyWalkerlab: Tocilizumab has been combined with Pembrolizumab previously in treatment of a patient with advanced melanoma and refract…

03 May 2020

Reply Repost Favourite

Tocilizumab has been combined with Pembrolizumab previously in treatment of a patient with advanced melanoma and refractory Crohn’s Disease. Induced durable antitumor responses with minimal exacerbation. 7/8 https://t.co/s0zoIdmKEa

03 May 2020

Reply Repost Favourite

Anti-IL6R ab for pts with pre-existing refractory Crohn's disease treated by checkpt inhib. : a novel strategy ? https://t.co/F1WVqoJgzh

27 Sep 2016

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.